STAT Reports

Deep dives into the breakthroughs that are revolutionizing health care

STAT Reports help you make sense of the ever-changing health and life sciences industries — and stay abreast of the latest companies, disruptive technologies, and personalities shaping the space.

STAT’s guide to interpreting clinical trial results

Interpreting clinical trial results is not for the faint of heart. Companies spin, short-sellers hawk, and everyone else is left swimming through the muck. But there is an art to reading scientific results — and you can learn it. In this report, STAT’s Sharon Begley and Adam Feuerstein provide basic tools to help you read clinical trial results with an appropriately skeptical (or at least critical) eye. They also examine specific examples of spin, noting the sections of papers reporting the results of clinical trials where they appear — and why that matters. Learn more about this report.

Biosimilars: What will it take to deliver on their promise?

Biosimilars — nearly identical versions of biologic drugs — have been heralded as a salve for the skyrocketing costs of prescription medications used to treat a wide variety of diseases. But so far they have been a disappointment. In this STAT Report, we dive into the regulations and manufacturing limitations that have acted as barriers to entry, as well as the companies that have managed to succeed in the space. Learn more about this report.

The STAT guide to viral vectors, the linchpin of gene therapy

Gene therapies were once dismissed as too dangerous to introduce to the treatment landscape. But today they are making a comeback with hundreds of products in the pipeline and under trial. In our latest STAT Report, we dive into the science, and business, of viral vector technologies. We spoke with executives from 18 companies to identify the pipeline of therapies that are nearing the clinic, the engineering and production challenges that may stifle progress, and how key players are looking to overcome those challenges. Learn more about this report.

Stay in the loop

To get alerts when new reports are released, sign up today.